🚨 [Strong Buy Alert] Is this laser stock in your portfolio?
There are very few opportunities like this in today's bear market...

But our analysts identified a tiny defense company landing billions of dollars in contracts every year.
Get the name of the company here >>>
Steve Miller net worth and biography

Steve Miller Biography and Net Worth

Steven R. Miller, PhD, is responsible for Catalyst’s product development program, which includes all aspects of chemistry and manufacturing controls, quality systems, contract operations, and development planning. Dr. Miller has 25 years of experience in the pharmaceutical and healthcare industries, joining Catalyst in 2007. Most recently he has managed Catalyst’s in-licensing of CPP-115 and Catalyst’s newest drug, Firdapse®, and taken these products through various preclinical and clinical development studies. Dr. Miller previously served as Executive Director for Research and Development Operations at Watson Pharmaceuticals and as Vice President of Research and Product Development at Royce Laboratories; he has also managed medical device development groups at Baxter Diagnostics and worked as an analytical chemist for the U.S. Food and Drug Administration. Dr. Miller received his doctorate in physical organic chemistry at the University of Miami; his work has been published in numerous technical and professional journals including Journal of Analytical Chemistry, Journal of the American Chemical Society, Journal of Medicinal Chemistry, and Chemical Communications.

What is Steve Miller's net worth?

The estimated net worth of Steve Miller is at least $9.56 million as of November 23rd, 2022. Dr. Miller owns 553,791 shares of Catalyst Pharmaceuticals stock worth more than $9,563,971 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Miller may own. Additionally, Dr. Miller receives a salary of $745,710.00 as COO at Catalyst Pharmaceuticals. Learn More about Steve Miller's net worth.

How old is Steve Miller?

Dr. Miller is currently 60 years old. There are 7 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO, who is 75 years old. Learn More on Steve Miller's age.

What is Steve Miller's salary?

As the COO of Catalyst Pharmaceuticals, Inc., Dr. Miller earns $745,710.00 per year. The highest earning executive at Catalyst Pharmaceuticals is Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO, who commands a salary of $1,050,000.00 per year. Learn More on Steve Miller's salary.

How do I contact Steve Miller?

The corporate mailing address for Dr. Miller and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected] Learn More on Steve Miller's contact information.

Has Steve Miller been buying or selling shares of Catalyst Pharmaceuticals?

During the past quarter, Steve Miller has sold $1,569,200.00 in shares of Catalyst Pharmaceuticals stock. Most recently, Steve Miller sold 20,000 shares of the business's stock in a transaction on Wednesday, November 23rd. The shares were sold at an average price of $17.34, for a transaction totalling $346,800.00. Following the completion of the sale, the chief operating officer now directly owns 553,791 shares of the company's stock, valued at $9,602,735.94. Learn More on Steve Miller's trading history.

Who are Catalyst Pharmaceuticals' active insiders?

Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Alicia Grande (CFO), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), and Steven Miller (COO & Chief Scientific Officer ). Learn More on Catalyst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Catalyst Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 24 times. They sold a total of 1,742,297 shares worth more than $26,268,304.10. The most recent insider tranaction occured on November, 23rd when COO Steve Miller sold 20,000 shares worth more than $346,800.00. Insiders at Catalyst Pharmaceuticals own 14.1 % of the company. Learn More about insider trades at Catalyst Pharmaceuticals.

Information on this page was last updated on 11/23/2022.

Steve Miller Insider Trading History at Catalyst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2022Sell20,000$17.34$346,800.00553,791View SEC Filing Icon  
11/21/2022Sell80,000$15.28$1,222,400.00573,791View SEC Filing Icon  
9/13/2022Sell107,933$16.90$1,824,067.70653,791View SEC Filing Icon  
8/18/2022Sell150,000$13.53$2,029,500.00761,724View SEC Filing Icon  
8/25/2021Sell80,000$5.56$444,800.00821,724View SEC Filing Icon  
1/11/2016Buy7,933$1.80$14,279.40457,687View SEC Filing Icon  
6/4/2014Buy100,000$2.17$217,000.00View SEC Filing Icon  
See Full Table

Steve Miller Buying and Selling Activity at Catalyst Pharmaceuticals

This chart shows Steve Miller's buying and selling at Catalyst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $17.27
Low: $16.51
High: $17.55

50 Day Range

MA: $14.28
Low: $12.09
High: $17.51

2 Week Range

Now: $17.27
Low: $5.24
High: $18.39

Volume

3,382,300 shs

Average Volume

1,969,081 shs

Market Capitalization

$1.80 billion

P/E Ratio

28.31

Dividend Yield

N/A

Beta

1.25
🚨 [Strong Buy Alert] Is this laser stock in your portfolio?
There are very few opportunities like this in today's bear market...

But our analysts identified a tiny defense company landing billions of dollars in contracts every year.
Get the name of the company here >>>